Ventus Therapeutics is a biopharmaceutical company discovering and developing novel small molecule medicines that target the innate immune system to treat autoimmune diseases, inflammatory diseases and cancer.
Ventus Therapeutics is focused on discovering and developing novel therapeutics that target the innate immune system with the goal of addressing autoimmune diseases, inflammatory diseases, and cancer.
Ventus Therapeutics was founded in 2019 by Hao Wu, Richard Flavell, Judy Lieberman, Thomas Tuschl, and Feng Shao. The company is headquartered in Montreal, Quebec, Canada, with an office in Natick, Massachusetts.
Ventus is applying structural immunology to discover and develop therapeutics targeting innate immune pathways to address human disease.
Ventus is uniquely enabled by its field-leading structural immunology platform, a highly experienced management and drug discovery team that has delivered multiple marketed compounds, and leading academics spanning the fields of structural biology and immunology.
Ventus’ platform brings together unique structural immunology capabilities to address these challenges and pursue some of the most important targets in the field. The platform employs proprietary protein engineering to solve molecular structures, enable novel binding and functional screening assays, and power structure-based modeling.
Ventus Therapeutics has raised $60M in a Series A round on May 06, 2020. The financing was led by founding investor Versant Ventures with participation by GV (formerly Google Ventures).